Tumor News and Research

RSS

Study finds breast MRI equipment in U.S. meets ACRIN and EUSOBI standards

An overwhelming majority of Breast Cancer Surveillance Consortium (BCSC) facilities performing breast magnetic resonance imaging (MRI) in the U.S. are up-to-par with American College of Radiology Imaging Network (ACRIN) and European Society of Breast Imaging (EUSOBI) technical standards and requirements, according to a study in the November issue of the Journal of the American College of Radiology.

1 Nov 2010

CyberKnife radiosurgery studies for breast cancer treatment to be presented at ASTRO Meeting

Accuray Incorporated, a global leader in the field of radiosurgery, announced today studies underway at two leading academic institutions using CyberKnife radiosurgery in breast cancer treatment. These two studies, from the University of Texas Southwestern and Fox Chase Cancer Center, will be presented at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO) in San Diego from October 31 to November 4.

1 Nov 2010

Philips launches HFO Oncology Configuration for radiation therapy

Royal Philips Electronics today introduced the Philips Panorama High Field Open (HFO) Oncology Configuration for radiation therapy, a magnetic resonance (MR) imaging solution for dedicated oncology use, at this year's American Society for Therapeutic Radiology and Oncology (ASTRO) in San Diego, CA.

From Philips Healthcare 1 Nov 2010

FDA approves Afinitor drug for tuberous sclerosis complex

The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.

1 Nov 2010

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today announced that data from preclinical studies of three investigational messenger RNA (mRNA) antagonists based on the locked nucleic acid (LNA) technology platform have been accepted for poster presentation at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, which is being held November 16-19 in Berlin, Germany.

30 Oct 2010

Accuray to present CyberKnife Robotic Radiosurgery System at ASTRO Meeting

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that 40 accepted abstracts highlighting the use of the CyberKnife Robotic Radiosurgery System will be presented as posters and presentations at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO), taking place in San Diego from October 31-November 4.

30 Oct 2010

Study finds SBRT therapy delays pancreatic cancer progression

For pancreatic cancer patients unable to undergo surgery the only known cure for this form of cancer a highly targeted cancer radiation therapy may help slow cancer progression and lessen disease symptoms, according to researchers at Henry Ford Hospital in Detroit.

30 Oct 2010

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it will present several poster presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases being held in Boston, Mass from October 29 - November 2, 2010.

30 Oct 2010

Advaxis enters CRADA with NCI for development of live attenuated Listeria vaccines

Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, is pleased to announce it has signed a formal research agreement with the National Cancer Institute at the National Institutes of Health.

30 Oct 2010

Study suggests microRNA binding site helps improved prognosis of colorectal cancer at early stage

A variant site linked to poor outcome in advanced colorectal cancer has now been found to predict improved prognosis in early stages of cancer, according to research presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

Mechanism that controls embryonic development could also prevent cancer

Researchers from Mount Sinai School of Medicine have identified a mechanism controlling the function of a protein that binds to DNA during embryonic development and may function to prevent abnormal tumor growth.

29 Oct 2010

Novel small molecule inhibitors may provide new therapy for colon cancer

Researchers are one step closer to providing a new therapy for colon cancer, after findings revealed that a small molecule focal adhesion kinase (FAK) inhibitor known as Y15 effectively blocked cell viability, promoted detachment and apoptosis, and decreased tumor growth in mice. These findings were presented at the American Association for Cancer Research special conference on Colorectal Cancer: Biology to Therapy, held Oct. 27-30, 2010.

29 Oct 2010

Research on Rictor protein may provide new molecular target for cancer treatment

The discovery that a protein called Rictor plays a key role in destroying a close cousin of the AKT oncogene could provide scientists with a new molecular target for treating certain cancers, including breast cancer. Described in the September 2010 issue of the journal Molecular Cell, the study was led by scientists at Beth Israel Deaconess Medical Center (BIDMC).

29 Oct 2010

57% of ALK-positive advanced non-small cell lung cancer patients respond to crizotinib: Study

A study in the New England Journal of Medicine shows more than half of patients with a specific kind of lung cancer are responding positively to a treatment that targets the gene that drives their cancer.

29 Oct 2010

Henry Ford Hospital physicist receives ASTRO's Basic Science Abstract Award

Henry Ford Hospital physicist Lei Ren, Ph.D., is among an elite group to be awarded for basic science research in radiation oncology at the 52nd annual American Society for Radiology Oncology (ASTRO) meeting in San Diego.

29 Oct 2010

ImmuneRegen's Homspera enhances survival of animals vaccinated with experimental melanoma vaccine

ImmuneRegen BioSciences, Inc.®, a wholly owned subsidiary of IR BioSciences Holdings, Inc., today announced that treatment with its lead compound, Homspera®, improved the survival of animals vaccinated with an experimental melanoma vaccine.

29 Oct 2010

New findings on Th17 cells pave way for human cancer treatment protocol

A recently identified immune cell that directs other cells to fight infection plays a critical role in regulating the immune system in both health and disease. Researchers from the University of Pennsylvania School of Medicine have discovered how a stimulatory molecule and a protein found on the membrane of another immune cell make T helper 17 cells multi-taskers of sorts. Th17 cells protect the body against infection and cancer, but are also culprits in some autoimmune diseases and out-of-control, cancerous cell growth.

29 Oct 2010

International Congress at Spain highlights advances in neuroimmunological disease treatment

The complexity of the immune system and nervous system turn Neuroimmunology into one of the most exciting fields of modern biomedicine. Between October 26th and 30th takes place in Sitges (Barcelona, Spain) the X International Congress of Neuroimmunology of the International Society of Neuroimmunology.

29 Oct 2010

Low levels of pre-treatment radiation do not risk radiotherapy efficacy in prostate, lung cancer patients

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit will present data that suggests low levels of pre-treatment radiation mimicking the doses delivered by CT scans for image guidance pose no risk to the efficacy of radiotherapy in patients with prostate carcinoma and non-small cell lung carcinoma. The findings will be formally announced on Sunday, Oct. 31, during the American Society of Therapeutic Radiology and Oncology (ASTRO) Annual Meeting.

29 Oct 2010

New approach for early diagnosis of pancreatic cancer

Pancreatic tumors are one of the most lethal cancers, with fewer than five percent of patients surviving five years after diagnosis. But a new study that peers deeply into the genetics of pancreatic cancer presents a bit of good news an opportunity for early diagnosis. In contrast to earlier predictions, many pancreatic tumors are, in fact, slow growing, taking nearly 20 years to become lethal after the first genetic perturbations appear.

29 Oct 2010

Tumor News and Research

Study finds breast MRI equipment in U.S. meets ACRIN and EUSOBI standards

CyberKnife radiosurgery studies for breast cancer treatment to be presented at ASTRO Meeting

Philips launches HFO Oncology Configuration for radiation therapy

FDA approves Afinitor drug for tuberous sclerosis complex

Enzon data on LNA technology platform accepted for presentation at EORTC-NCI-AACR Symposium

Accuray to present CyberKnife Robotic Radiosurgery System at ASTRO Meeting

Study finds SBRT therapy delays pancreatic cancer progression

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Advaxis enters CRADA with NCI for development of live attenuated Listeria vaccines

Study suggests microRNA binding site helps improved prognosis of colorectal cancer at early stage

Mechanism that controls embryonic development could also prevent cancer

Novel small molecule inhibitors may provide new therapy for colon cancer

Research on Rictor protein may provide new molecular target for cancer treatment

57% of ALK-positive advanced non-small cell lung cancer patients respond to crizotinib: Study

Henry Ford Hospital physicist receives ASTRO's Basic Science Abstract Award

ImmuneRegen's Homspera enhances survival of animals vaccinated with experimental melanoma vaccine

New findings on Th17 cells pave way for human cancer treatment protocol

International Congress at Spain highlights advances in neuroimmunological disease treatment

Low levels of pre-treatment radiation do not risk radiotherapy efficacy in prostate, lung cancer patients

New approach for early diagnosis of pancreatic cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News